Latest Regulatory Approvals News

A1 Investments & Resources Ltd reported a modest cash outflow for Q1 2024 while actively pursuing renewable energy acquisitions in Japan and Australia, contingent on regulatory approvals and shareholder consent.

Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.

Tivan Limited has advanced its Speewah Fluorite Project with a $7.4 million government grant and Major Project Status, alongside a joint venture MoU with Sumitomo Corporation and promising drilling results at Sandover.

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.

Lanthanein Resources has completed initial drilling phases at its Lady Grey Project and secured a six-month extension on its farm-in agreement, positioning the company for a critical assessment of its gold exploration prospects.

Patronus Resources reports significant drilling progress across its Western Australia and Northern Territory projects, with strong assay results at Mertondale and a robust cash position supporting ongoing exploration.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

NGX Limited reports significant progress in its uranium exploration in Namibia and graphite development in Malawi, alongside strategic leadership changes and a strong financial position.

Arafura Rare Earths has secured a pivotal A$200 million investment commitment from the National Reconstruction Fund Corporation, advancing its Nolans Project towards a final investment decision targeted for mid-2025.